Eli Lilly will ask the FDA to approve retatrutide in the first quarter of 2027, a timeline that puts a best-in-class obesity candidate on a collision course with Novo Nordisk's franchise just as the market is still absorbing Zepbound's launch. The filing date is the first concrete marker for a drug that has already posted weight-loss numbers no approved medicine has matched.
The efficacy bar just moved
In a phase 3 study, retatrutide delivered an average weight loss of 28.3 percent over 80 weeks. That figure sits above anything Wegovy has produced in clinical trials and, as investigators have noted, lands in the range typically associated with bariatric surgery. The mechanism, a triple agonist targeting GIP, GLP-1 and glucagon receptors, suggests the efficacy gap is structural, not statistical. Patients with diabetes, a population that historically responds less aggressively to GLP-1 therapies, also showed significant reductions.
The quarter that funded the pipeline
Second-quarter revenue rose 48 percent year over year to $23 billion. Adjusted earnings per share climbed 33 percent to $8.38. Both results beat consensus and sent the stock modestly higher. The beat was driven by incretin sales, but the cash flow is already being redeployed across oncology and immunology programs that management says will reach meaningful milestones over the next few years.
What Novo Nordisk is up against
Novo Nordisk now faces a competitor that does not intend to cede the high-BMI segment where current therapies plateau. Retatrutide's additional investigations, obstructive sleep apnea, chronic back pain, metabolic dysfunction-associated steatotic liver disease, expand the addressable population beyond weight loss alone. The risk for Novo is not just share erosion in obesity but a broader re-rating of what the category's ceiling looks like.
The pipeline beyond weight loss
Lilly's guidance implies the incretin franchise is a cash engine, not the whole thesis. Oncology and immunology assets are advancing on their own timelines, and the company has signaled it expects progress in those markets to become visible in the medium term. If retatrutide files on schedule and the diversified pipeline delivers, the revenue base that supported a 48 percent quarterly jump could prove durable rather than cyclical.